Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms Tumor Gene) expression levels

Blood

Volumn 88, Issue 6, 1996, Pages 2267-2278

  Inoue, Kazushi ^b   Ogawa, Hiroyasu ^b   Yamagami, Tamotsu ^b   Soma, Toshihiro ^b   Tani, Yoshihiko ^b   Tatekawa, Toyoshi ^b   Oji, Yusuke ^b   Tamaki, Hiroya ^b   Kyo, Taiichi ^b   Dohy, Hiroo ^b   Hiraoka, Akira ^b   Masaoka, Tohru ^b   Kishimoto, Tadamitsu ^b   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; FOLLOW UP; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEPHROBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 9544233528     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.2267.bloodjournal8862267     Document Type: Article

References (50)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509, 1990
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774, 1990
3. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88:9618, 1991
4. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ III: Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257:674, 1992
5. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ III, Collins T, Sukhatme VP: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 89:10984, 1992
6. Harrington MA, Konicek B, Song A, Xia X-L, Fredericks WJ, Rauscher FJ III: Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 268:21271, 1993
7. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ III, Sens DA, Garvin AJ, LeRoith D, Roberts CT Jr: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 90:5828, 1993
8. Wang Z-Y, Qiu Q-Q, Deuel TF: The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem 268:9172, 1993
9. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ III, Hill DE, Harber DA: Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 90:5100, 1993
10. Coppes MJ, Campbell CE, Williams BRG: The role of WT1 in Wilms tumorigenesis. FASEB J 7:886, 1993
11. Rauscher FJ III: The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 7:896, 1993
12. Haber DA, Park S, Maheswaran S, Englert C, Re GG, HazenMartin DJ, Sens DA, Garvin AJ: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 262:2057, 1993
13. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, Haber DA: The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415, 1993
14. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071, 1994
15. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T, Kishimoto T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878, 1996
16. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550, 1985
17. Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD, Croce CM: A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukemia. Nature 330:386, 1987
18. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85:5698, 1988
19. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitovsky E, Evans RM: Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor, PML. Cell 66:663, 1991
20. de The H, Lavau C, Marcio A, Chomienne C, Degos L, Dejean A: The PML-RAR-α fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
21. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the morphogen retinoic acid. Nature 330:624, 1987
22. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, DeBlasio A, Levine K, Evans RM, Dmitovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694, 1992
23. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin CI, Erickson P: An AMLI/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81:2860, 1993
24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): A report of the French-American-British Cooperative Group. Ann Intern Med 103:460, 1985
25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:626, 1985
26. Yumura-Yagi K, Hara J, Kurahashi H, Okamura J, Koizumi S, Toyoda Y, Maruyama N, Inoue M, Ishihara S, Tawa A, Nishiura T, Kaneyama Y, Okada S, Kawa-Ha K: Clinical significance of CD7-positive stem cell leukemia. Cancer 68:2273, 1991
27. Inoue K, Sugiyama H, Ogawa H, Yamagami T, Azuma T, Oka Y, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Hara J, Kanamaru A, Kishimoto T: Expression of the IL-6, IL- 6 receptor, and gp130 genes in acute leukemia. Blood 84:2672, 1994
28. Gray JW, Kuo WL, Liang J, Pinkel D, Van den Engh G, Trask B, Tkachuk D, Waldman F, Westbrook C: Analytical approaches to detection and characterization of disease-linked chromosome aberrations. Bone Marrow Transplant 6:14, 1990
29. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416, 1995
30. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane SS, Lange B, Tsujimoto Y, Caton AJ, Rovera G: Detection of minimal disease in haemopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 86:5123, 1989
31. MacIntyre EA, d'Auriol L, Duparc N, Leveger G, Galibert F, Sigaux F: Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable (diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. J Clin Invest 86:2125, 1990
32. Kolb HJ, Mittermüller J, Clemm Ch, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
33. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79:1379, 1992
34. Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL: Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 10:301, 1992
35. Bär BMAM, Schattenberg A, Mensink EJBM, Geurts Van Kessel A, Smetsers TFCM, Knops GHJN, Linders EHP, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513, 1993
36. Coco FL, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T, Pelicci PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340:1437, 1992
37. Huang W, Sun G-L, Li X-S, Cao Q, Lu Y, Jang G-S, Zhang F-Q, Chai J-R, Wang Z-Y, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: Clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retro-transcriptase/polymerase chain reaction to predict relapse. Blood 82:1264, 1993
38. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-a fusion mRNA. Blood 82:1689, 1993
39. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci PG, Coco FL: Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 82:3556, 1993
40. Diverio D, Pandolfi PP, Rossi V, Biondi A, Pelicci PG, Coco FL: Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 8:S63, 1994 (suppl 2)
41. Koller E, Karlic H, Krieger O, Mistrik M, Michlmayr G, Gadner H, Lutz D, Heinz R, Pittermann E: Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. Ann Hematol 70:75, 1995
42. Pignon JM, Henni T, Amselem S, Vidaud M, Duquesnoy P, Vernant JP, Kuentz M, Cordonnier C, Rochant H, Goossens M: Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 4:83, 1990
43. Delfau M-H, Kerckaert J-P, d'Hooghe MC, Fenaux P, Lai J-L, Jouet J-P, Grandchamp B: Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia 4:1, 1990
44. Hughes TP, Morgan GJ, Martiat P, Goldman JM: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 77:874, 1991
45. Xu WM, Piao XH, Addy L, Jamal N, Minden MD, Messner HA: Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia. Bone Marrow Transplant 14:299, 1994
46. Nucifora G, Larson RA, Rowley JD: Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712, 1993
47. Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U: AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994
48. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L: The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8:2138, 1994
49. Martin H, Atta J, Bruecher J, Elsner S, Schardt C, Stadler M, von Melcher H, Hoelzer D: In patients with BCR-ABL positive ALL in CR peripheral blood contains less residual disease than bone marrow: Implications for autologous BMT. Ann Hematol 68:85, 1994
50. Cross NCP, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse. Br J Haematol 84:67, 1993